1,1-bis(allyloxy)butane | 35020-94-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1-bis(allyloxy)butane
• 英文别名: butyraldehyde diallyl acetal；Diallyl-butyral；1,1-Bis-allyloxy-butan；1,1-Bis[(prop-2-en-1-yl)oxy]butane；1,1-bis(prop-2-enoxy)butane
• CAS: 35020-94-1
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: UYSVKUWLZQFGJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-bis(allyloxy)butane 生成 烯丙醇
  参考文献：
  名称：

  OKURA, KADZUXIRO;KUBO, MASAAKI

  摘要：

  DOI：
• 作为产物：
  描述：

  正丁醛 在 对甲苯磺酸一水合物 、 magnesium sulfate 、 potassium carbonate 作用下， 以 正己烷 、 水 为溶剂， 生成 1,1-bis(allyloxy)butane
  参考文献：
  名称：

  Method for Producing Bicyclic Compound via Claisen Rearrangement

  摘要：

  本发明要解决的问题是提供一种生产作为α2δ配体具有优异活性的化合物的方法。其解决方法是使用重排反应生产由通式（VI）表示的化合物或其盐：[在公式中，R1：氢原子或C1-C6烷基]。

  公开号：

  US20140094623A1

文献信息

• Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070112031A1

  公开（公告）日：2007-05-17

  Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

  化学合成和新型单胺神经递质摄取抑制剂的医药用途，以及其药用盐和前药，用于治疗和/或管理精神疾病、焦虑症、广泛性焦虑症、抑郁症、创伤后应激障碍、强迫症、恐慌症、潮热、老年痴呆症、偏头痛、肝肺综合征、慢性疼痛、伤害性疼痛、神经病性疼痛、疼痛性糖尿病视网膜病变、双相抑郁症、阻塞性睡眠呼吸暂停、精神疾病、经前期失调性障碍、社交恐惧症、社交焦虑症、尿失禁、厌食症、暴食症、肥胖症、缺血、头部损伤、脑细胞钙超载、药物依赖和/或早泄。
• PREPARATION AND UTILITY OF SUBSTITUTED INDOLES
  申请人：Gant G. Thomas

  公开号：US20080103189A1

  公开（公告）日：2008-05-01

  Disclosed herein are substituted indoles of Formula I, processes of preparation there of, pharmaceutical compositions thereof, and methods of their use there of.

  本文揭示了公式I的取代吲哚化合物，其制备方法，药物组合物以及它们的使用方法。
• [EN] MANUFACTURE OF EPOXYETHYL ETHERS OR GLYCIDYL ETHERS<br/>[FR] FABRICATION D'ÉTHERS D'ÉPOXYÉTHYLE OU D'ÉTHERS DE GLYCIDYLE
  申请人：MOMENTIVE SPECIALTY CHEMICALS RES S A

  公开号：WO2011095293A1

  公开（公告）日：2011-08-11

  Processes are provided for the formation of an epoxyethyl ether or a glycidyl ether, hi one embodiment, a process is provided for the manufacture of an epoxyethyl ether or glycidyl ether including reacting a vinyl ether or an allyl ether with an oxidant in the presence of a water-soluble manganese complex in an aqueous reaction medium, wherein the water-soluble manganese complex comprises an oxidation catalyst, characterized in that the water-soluble manganese complex is a mononuclear complex of the general formula (I): [LMnX3]Y (I), or a binuclear complex of the general formula (II): [LMn(μ-X)3MnL](Y)n (II), wherein Mn is a manganese; L or each L independently is a polydentate ligand, each X independently is a coordinating species and each μ-X independently is a bridging coordinating species, Y is a non-coordinating counter ion, and wherein the epoxidation is carried out at a pH in the range of from 1.0 to 6.0. The invention also relates to epoxyethyl ethers.

  提供了一种形成环氧乙基醚或环氧基醚的工艺。在一个实施例中，提供了一种用于制造环氧乙基醚或环氧基醚的工艺，包括在水溶性锰配合物存在的水相反应介质中，将乙烯醚或烯丙基醚与氧化剂反应，其中水溶性锰配合物包括氧化催化剂，其特征在于水溶性锰配合物是通式(I)的单核配合物：[LMnX3]Y (I)，或通式(II)的双核配合物：[LMn(μ-X)3MnL](Y)n (II)，其中Mn是锰；L或每个L独立地是多齿配体，每个X独立地是一个配位物种，每个μ-X独立地是一个桥联配位物种，Y是一个非配位的反离子，环氧化在pH值为1.0至6.0的范围内进行。该发明还涉及环氧乙基醚。
• Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070082929A1

  公开（公告）日：2007-04-12

  Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

  描述了用于治疗和/或管理十二指肠溃疡、胃灼热、酸反流、其他由胃酸分泌介导的疾病以及牛皮癣的新型胃H+、K+-ATP酶抑制剂的化学合成和医学用途。
• Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
  申请人：Sarshar Sepehr

  公开号：US20080234229A1

  公开（公告）日：2008-09-25

  The present invention is directed to compounds having the structure Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. In particular, the invention relates to compounds that induce apoptosis of cancer cells and therefore may be used for the treatment or prevention of cancer, including advanced cancers and pre-cancerous cells. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.

  本发明涉及具有结构式（I）的化合物，其中R1、R2、R3、R4、R5和m的定义如本文所述。本发明的化合物是哺乳动物主体中治疗癌症、代谢性疾病和皮肤疾病的新型治疗剂。这些化合物也是有用的基因表达调节剂。它们通过干扰某些细胞信号转导级联来发挥作用。因此，本发明的化合物也有助于调节由各种激素或细胞因子控制或调节的细胞分化和细胞周期过程。特别是，本发明涉及诱导癌细胞凋亡的化合物，因此可用于治疗或预防癌症，包括晚期癌症和癌前细胞。本发明还揭示了哺乳动物疾病的药物组成和治疗方法。